Agenus Story

<div class='circular--portrait' style='background:#169D0B;color: #FFFFF0;font-size:3em;'>AGE</div>
AGEN -- USA Stock  

USD 2.66  0.03  1.12%

Today we may see the proof that Editas Medicine would recover slower from the newest drop as its shares fell 2.2% to Agenus's 1.19%. As many of us are excited about healthcare space, we will review both, Agenus and Editas Medicine as a potential short-term opportunity. We are going to inspect some of the competitive aspects of both Agenus and Editas.
Published over a month ago
View all stories for Agenus | View All Stories
Is Editas more volatile than Agenus Inc (NASDAQ:AGEN)?
By analyzing existing technical and fundamental indicators between Agenus and Editas, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Editas with a short position in Agenus. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Agenus has an asset utilization ratio of 102.64 percent. This suggests that the company is making $1.03 for each dollar of assets. An increasing asset utilization means that Agenus Inc is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Agenus or Dicerna is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Agenus's Liquidity

Agenus financial leverage refers to using borrowed capital as a funding source to finance Agenus Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Agenus financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Agenus's total debt and its cash.

Correlation Between Agenus and Dicerna Pharmaceutic

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Agenus together with similar or unrelated positions with a negative correlation. For example, you can also add Dicerna Pharmaceutic to your portfolio. If Dicerna Pharmaceutic is not perfectly correlated to Agenus it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Agenus for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Please check pair correlation details between AGEN and DRNA for more information.

Note

Are you currently holding both Agenus and Dicerna Pharmaceutic in your portfolio?
Please note if you are using this as a pair-trade strategy between Agenus and Dicerna Pharmaceutic, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses.

Acquisition by Hirsch Susan B of 5092 shares of Agenus subject to Rule 16b-3

Legal trades by Agenus insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Agenus insider trading alert for grant of common stock by Hirsch Susan B, the corporate stakeholder, on 5th of April 2021. This event was filed by Agenus Inc with SEC on 2021-04-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Agenus Investor Appetite?

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Lets now check Agenus revenue. Based on the latest financial disclosure, Agenus Inc reported 91.41 M of revenue. This is 98.8% lower than that of the Healthcare sector and 87.7% lower than that of the Biotechnology industry. The revenue for all United States stocks is 99.03% higher than that of Agenus. As for Editas Medicine we see revenue of 90.73 M, which is 87.79% lower than that of the Biotechnology

Sector
742.9 M
AGEN91.41 Million9.88
Sector742.91 Million80.31
EDIT90.73 Million9.81

Another setback for Agenus institutional investors

Latest Market Risk Adjusted Performance is up to 0.09. Price may slide again. Agenus Inc shows above-average downside volatility for the selected time horizon. We advise investors to inspect Agenus Inc further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Agenus future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Agenus' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Agenus' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Takeaway on Agenus Investment

Whereas other companies in the biotechnology industry are either recovering or due for a correction, Agenus may not be performing as strong as the other in terms of long-term growth potentials. While some institutional investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Agenus.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Agenus Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com